We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Glycosylated Hemoglobin Predicts Coronary Artery Disease in Non‐Diabetic Patients

By LabMedica International staff writers
Posted on 27 Oct 2020
Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide. More...
CAD remains as a leading reason for heart failure causing disability and not only outcomes in the need for life‐long therapies, but also causes sudden death with acute myocardial infarction.

Diabetes mellitus is a common metabolic disorder characterized by absolute or relative deficiencies in insulin secretion and/or insulin action associated with chronic hyperglycemia and with an increased risk of microvascular and macrovascular disease. Glycosylated hemoglobin (HbA1c) is a marker of three‐month blood sugar levels. Long‐term high blood sugar levels have been shown to pose a risk of cardiovascular disease.

Medical scientists at the Bezmialem Vakif University (Istanbul, Turkey) included in a study 247 patients without diabetes type 2 who were admitted to the outpatient clinic of the Cardiology department from January 2016 to June 2018 in a university hospital. Of the 247 cases whose 41.7% were women. The ages of the patients ranged from 33 to 87 years with a mean age of 60 ± 10.9 years. The non‐diabetic patients with HbA1c value below 6.5% who underwent elective coronary angiography (CAG) with various indications were included in the study.

In addition to obtaining HbA1c results of all patients included in the study, other biochemical tests performed before angiography including high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), triglyceride (TG), liver function tests (AST, ALT), and electrolytes (Na, K, Ca). Demographic characteristics and known chronic diseases were investigated by face‐to‐face interviews. Of the study group, 120 patients were without any stenosis in any coronary artery, 56 patients were with >50% stenosis in one coronary artery, and 71 patients were with >50% stenosis in more than one coronary artery.

The scientists reported that in their study, HbA1c measurements ranged from 4.48% to 6.49% (5.7% ± 0.54) in whole study group and were lower than 5.69% among 44.5% (n = 110) of the cases, and however, it was between 5.7% and 6.5% in 55.5%. Stenosis positive ratio was found to be significantly higher in cases with HbA1c level of 5.7%‐6.5% than those with HbA1c level of less than 5.69%. HbA1c level 5.7%‐6.5% significantly increases the risk of stenosis. The odd ratio for HbA1c was 6.260. According to the stenosis positivity, the cutoff point for HbA1c was found to be 5.6% and above. In the regression analysis, HbA1c was an independent risk factor for CAD. One unit increase in HbA1c level increases the risk of stenosis up to 12.4‐fold.

The authors concluded that their study showed HbA1c can be used as an independent marker in determining the probability and severity of coronary artery disease in non‐diabetic individuals and as a useful marker in primary care predicting CAD. The study was published on October 9, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Bezmialem Vakif University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.